News - Nexavar

Filter

Current filters:

Nexavar

Popular Filters

19 to 33 of 33 results

Indian hearings on Bayer Nexavar compulsory license delayed

22-08-2012

India's Intellectual Property Appellate Board (IPAB) in Chennai has postponed hearing the appeal by German…

Asia-PacificBayerGenericsLegalNatco PharmaNexavarOncologyPatentsPharmaceutical

Adding Tarceva to Nexavar no better than Nexavar alone for liver cancer

23-07-2012

A Phase III trial evaluating the efficacy and safety of the addition of Roche's Tarceva (erlotinib) tablets…

Astellas PharmaBayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearchTarceva

Bristol-Myers brivanib fails in Ph III liver cancer trial

20-07-2012

US drug major Bristol-Myers Squibb (NYSE: BMY) yesterday reported results of the Phase III BRISK-FL clinical…

Bristol-Myers SquibbbrivanibNexavarOncologyPharmaceuticalResearch

Bayer and Onyx' Nexavar fails in Ph III lung cancer study

23-05-2012

There was disappointment for German drug major Bayer (BAYB: DE) and partner Onyx Pharmaceuticals (Nasdaq:…

BayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearch

Pfizer's Torisel fails in Ph III advanced renal cell cancer study

17-05-2012

There was disappointment for global pharma behemoth Pfizer (NYSE: PFE) when it said that the Phase III…

BayerNephrology and HepatologyNexavarOncologyPfizerPharmaceuticalResearchTorisel

Bayer challenges Indian ruling on Nexavar patent

08-05-2012

German drug major Bayer (BAYN: DE) has launched an appeal against the Indian Patent Office, which a couple…

Asia-PacificBayerGenericsLegalNexavarOncologyPatentsPharmaceutical

Cipla slashes price of generic cancer drug Nexavar in India by 76%; other cuts too

04-05-2012

Indian drugmaker Cipla (BSE: 500087) has slashed the prices of certain life-saving cancer drugs used…

Asia-PacificAstraZenecaBayerCiplaGenericsIressaMerck & CoNexavarOncologyPharmaceuticalPricingTemodar

Reimbursement and/or budget-related factors restrict use of angiogenesis inhibitor in Brazil and Mexico; Study

28-03-2012

Depending on the tumor type, around one-quarter to one-third of surveyed Brazilian and Mexican oncologists'…

AvastinMarkets & MarketingNexavarOncologyPharmaceuticalPricingSouth AmericaSutent

India issues compulsory license for Bayer cancer drug Nexavar

13-03-2012

The Indian Patent Office has issued the first-ever compulsory licence in India to a generic drug manufacturer.…

Asia-PacificBayerGenericsNatco PharmaNexavarOncologyPatentsPharmaceutical

Three “targeted” cancer drugs slightly raise fatal side effects risk, says Dana-Faber Inst

08-02-2012

2 Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated…

NexavarOncologyPharmaceuticalResearchSutentVotrient

Bayer settles with Onyx over Nexavar and regorafenib with $160 million payment

13-10-2011

US drugmaker Onyx Pharmaceuticals (Nasdaq: ONXX) and German pharma major Bayer HealthCare, a unit of…

BayerLegalLicensingNexavarOncologyOnyx PharmaceuticalsPharmaceuticalregorafenib

Roundup of upcoming cancer drug trials to be presented at ASCO

20-05-2011

A number of leading pharmaceutical companies – include Pfizer, Bayer, Roche and AstraZeneca - have…

AstraZenecaaxitinibBayerMetMAbNexavarolaparibOncologyPfizerPharmaceuticalResearchRoche

Low-dose sorafenib may improve therapy for head and neck cancer, Ohio researchers find

17-05-2011

Adding low doses of the targeted agent sorafenib (German drug major Bayer and Onyx’ kidney and liver…

BayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearch

19 to 33 of 33 results

Back to top